A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection

Chen, Binfan; Chen, Yu‐Chen; Li, Jian; Wang, Qianqian; Song, Wenping; Wen, Yumei; Lin, Jinzhong; Wu, Yanling; Ying, Tianlei

doi:10.1128/mbio.01612-22

Cited by 16 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that the injection of a single dose of LNPs containing both G12-scFv-Fc mRNA and G12-IgG mRNA significantly reduced the serum HBsAg level in treated mice within 30 days. 206 Hepatitis C virus (HCV). Dallas et al utilized short synthetic shRNA (sshRNA)-encapsulated LNPs to silence the expression of genes associated with the HCV internal ribosome entry site.…”

Section: (C) and (D))mentioning

confidence: 99%

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Chu,

Wang,

Kong

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: (C) and (D))mentioning

confidence: 99%

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Chu,

Wang,

Kong

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“… 101 Additionally, mRNA vaccines offer a novel approach for chronic virus infections such as HBV. 102 A mRNA-based vaccine for treating Hepatitis B virus-associated hepatocellular carcinoma (HCC) (NCT05738447) is currently undergoing clinical trial.…”

Section: Classifying Mrna Cancer Vaccinesmentioning

confidence: 99%

Recent progress in mRNA cancer vaccines

Yao,

Xie,

Xia

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments.

show abstract

“…The use of mRNA to encode antibody transgenes has been tested for a multitude of indications, including pathogens [51,[59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74], toxins [65,75,76], and cancers [65,[77][78][79][80][81][82] (Table 2. Current approaches for mRNA delivery of antibodies).…”

Section: Modified Mrna For Delivery Of Broadly Neutralizing Antibodiesmentioning

confidence: 99%

Delivery platforms for broadly neutralizing antibodies

Joshi

Gálvez

Ghosh

et al. 2023

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of reviewPassive administration of broadly neutralizing antibodies (bNAbs) is being evaluated as a therapeutic approach to prevent or treat HIV infections. However, a number of challenges face the widespread implementation of passive transfer for HIV. To reduce the need of recurrent administrations of bNAbs, gene-based delivery approaches have been developed which overcome the limitations of passive transfer.Recent findingsThe use of DNA and mRNA for the delivery of bNAbs has made significant progress. DNA-encoded monoclonal antibodies (DMAbs) have shown great promise in animal models of disease and the underlying DNA-based technology is now being tested in vaccine trials for a variety of indications. The COVID-19 pandemic greatly accelerated the development of mRNA-based technology to induce protective immunity. These advances are now being successfully applied to the delivery of monoclonal antibodies using mRNA in animal models. Delivery of bNAbs using viral vectors, primarily adeno-associated virus (AAV), has shown great promise in preclinical animal models and more recently in human studies. Most recently, advances in genome editing techniques have led to engineering of monoclonal antibody expression from B cells. These efforts aim to turn B cells into a source of evolving antibodies that can improve through repeated exposure to the respective antigen.SummaryThe use of these different platforms for antibody delivery has been demonstrated across a wide range of animal models and disease indications, including HIV. Although each approach has unique strengths and weaknesses, additional advances in efficiency of gene delivery and reduced immunogenicity will be necessary to drive widespread implementation of these technologies. Considering the mounting clinical evidence of the potential of bNAbs for HIV treatment and prevention, overcoming the remaining technical challenges for gene-based bNAb delivery represents a relatively straightforward path towards practical interventions against HIV infection.

show abstract

A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection

Cited by 16 publications

References 38 publications

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Recent progress in mRNA cancer vaccines

Delivery platforms for broadly neutralizing antibodies

Contact Info

Product

Resources

About